


Targeting the IAPs for cancer immunotherapy



Evasion of cell death is recognized as one of the key hallmarks of cancer. Members of the Inhibitor of Apoptosis (IAP) gene family are key oncogenes found in many solid and blood cancers. Consequently, targeting the IAPs is a promising therapeutic approach against cancer. A class of drugs called SMAC mimetics have been developed to antagonize the function of the IAPs. I will highlight our recent research into understanding the mechanism of SMAC mimetic efficacy and of the potential of this class of IAP antagonists to potentiate immune-based therapies for the treatment of cancer.



Shawn Beug

Scientist, CHEO Research Institute
Assistant Professor, uOttawa,
Department of Biochemistry,
Microbiology and Immunology
Canada Research Chair (Tier 2)

When

Date: September 28, 2023

Time: 12 - 1pm

In Person registration

Zoom registration

 **healthscienceCU**

carleton.ca/healthsciences



Carleton
University

Department of
Health Sciences